Highlights and Quick Summary
Current P/FCF ratio of AbbVie Inc. is 10.64 (as of December 30, 2020)
- P/FCF ratio for the quarter ending December 30, 2020 was 10.64 (a 5.23% increase compared to previous quarter)
- Year-over-year quarterly P/FCF ratio increased by 27.77%
- Annual P/FCF ratio for 2020 was 10.64 (a 3.62% increase from previous year)
- Annual P/FCF ratio for 2019 was 10.27 (a -7.58% decrease from previous year)
- Annual P/FCF ratio for 2018 was 11.11 (a -33.3% decrease from previous year)
Visit stockrow.com/ABBV
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical P/FCF ratio of AbbVie Inc.
Most recent P/FCF ratioof ABBV including historical data for past 10 years.Interactive Chart of P/FCF ratio of AbbVie Inc.
AbbVie Inc. P/FCF ratio for the past 10 Years (both Annual and Quarterly)
Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
---|---|---|---|---|---|
2020 | 10.64 | 10.11 | 11.46 | 8.33 | 10.64 |
2019 | 10.27 | 8.67 | 8.51 | 9.08 | 10.27 |
2018 | 11.11 | 12.04 | 13.49 | 14.62 | 11.11 |
2017 | 16.65 | 17.07 | 17.39 | 15.86 | 16.65 |
2016 | 15.43 | 14.8 | 13.16 | 12.19 | 15.43 |
2015 | 13.75 | 20.18 | 27.0 | 24.0 | 13.75 |
2014 | 35.54 | 19.35 | 18.66 | 15.88 | 35.54 |
2013 | 14.53 | 12.87 | 10.79 | 11.5 | 14.53 |
2012 | 9.21 | 9.21 | 9.21 | 9.21 | 9.21 |
2011 | 9.21 | 9.21 | 9.21 | 9.21 | 9.21 |
2010 | – | – | – | – | 9.21 |
Business Profile of AbbVie Inc.
Sector: Healthcare
Industry: Drug Manufacturers—General
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.